Skip to main content

Table 1 Clinicopathological parameters

From: Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study

Variables ER-Positive ER-Negative
Age<35 35≤Age≤50 P-value Age<35 35≤Age≤50 P-value
(N = 147) (N = 901) (N = 134) (N = 663)
Year of diagnosis       0.585
 1991–1995 1 (0.7) 3 (0.3)   1 (0.7) 2 (0.3)  
 1996–2000 4 (2.7) 3 (0.3)   1 (0.7) 8 (1.2)  
 2001–2005 24 (16.3) 111 (12.3)   25 (18.7) 97 (14.6)  
 2006–2010 90 (61.2) 557 (61.8)   75 (56.0) 411 (62.5)  
 2011–2013 28 (19.0) 227 (25.2)   32 (23.9) 145 (23.9)  
Histology    0.696    0.924
 Ductal 140 (95.2) 846 (93.9)   128 (95.5) 633 (95.5)  
 Lobular 3 (2.0) 30 (3.3)   0 (0.0) 2 (0.3)  
 Other 1 (0.7) 5 (0.6)   2 (1.5) 8 (1.2)  
 Unknown 3 (2.0) 20 (2.2)   4 (3.0) 20 (3.0)  
PR    0.379    0.674
 Negative 45 (30.6) 244 (27.1)   115 (85.8) 578 (87.2)  
 Positive 102 (69.4) 656 (72.8)   19 (14.2) 85 (12.8)  
 Unknown 0 (0.0) 1 (0.1)   0 (0.0) 0 (0.0)  
HER2    0.404    0.012
 Negative 106 (73.6) 674 (75.6)   104 (77.6) 429 (64.9)  
 Positive 37 (25.7) 215 (24.1)   29 (21.6) 218 (33.0)  
 Unknown 4 (2.7) 12 (1.3)   1 (0.7) 16 (2.4)  
Clinical Tumor size    1.000    0.745
 ≤ 2 cm 3 (2.0) 20 (2.2)   2 (1.5) 14 (2.1)  
 > 2 cm 49 (33.3) 290 (32.2)   51 (38.1) 210 (31.7)  
 Unknown 95 (64.6) 591 (65.6)   81 (60.4) 439 (66.2)  
Palpability    0.175    0.160
 Nonpalpable 1 (0.7) 29 (3.2)   1 (0.7) 27 (4.1)  
 Palpable 113 (76.9 650 (72.1)   95 (70.9) 459 (69.2)  
 Unknown 33 (22.4) 222 (24.6)   38 (28.4) 177 (26.7)  
Nucleus grade    0.110    0.102
 I 10 (6.8) 85 (9.4)   1 (0.7) 14 (2.1)  
 II 48 (32.7) 359 (39.8)   28 (20.9) 106 (16.0)  
 III 54 (36.7) 271 (30.1)   57 (42.6) 350 (52.8)  
 Unknown 35 (23.8) 186 (20.6)   48 (35.8) 193 (29.1)  
Proliferative index    0.001    0.006
 Low 79 (53.7) 612 (67.9)   19 (14.2) 184 (27.8)  
 High 52 (35.4) 210 (23.3)   91 (67.9) 378 (57.0)  
 Unknown 16 (10.9) 79 (8.8)   24 (17.9) 74 (11.2)  
  1. NOTE: Data are presented as No. (%) unless otherwise specified
  2. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2